Prime Minister Ana Brnabic visited today the pharmaceutical company Hemofarm together with representatives of the Government and the diplomatic corps, where she was introduced to the innovative drug Corpos for patients with multiple sclerosis (MS).
Q:
A:
Innovative drug against multiple sclerosis available to patients in Serbia
Vrsac,
29 March 2023
Brnabic pointed out that this drug is also available to patients in Serbia thanks to the cooperation between Hemofarm and the biggest biotechnology company Roche.
The production of the first innovative drug for the treatment of patients with multiple sclerosis has begun in Serbia, which will significantly change the course of the disease and improve the quality of life of patients, the Prime Minister stated.
She pointed out that negotiations are underway with Hemofarm about the wider production of other innovative drugs in our country, and pointed out that in the last four years, the number of MS patients treated by the Serbian Health Insurance Fund has quadrupled.
Brnabic recalled that in 2019 their number was 1,000, and currently there are 4,000, and noted that the funds allocated from the budget for the treatment of patients suffering from rare diseases have increased 33 times in 10 years.
-
Belgrade, 29 May 2023BIO4 campus project to ensure country’s further sustainable growth
-
Belgrade, 29 May 2023Situation in Kosovo and Metohija has never been more difficult
-
Belgrade, 25 May 2023Improvement of strategic cooperation with Azerbaijan
-
Belgrade, 25 May 2023Very good cooperation between government, state institutions with OSCE Mission
-
Belgrade, 25 May 2023Business, economic cooperation with US at its highest
-
Belgrade, 22 May 2023Support of UNICEF through expert assistance to youth
-
Belgrade, 18 May 2023Government continues implementing measures to combat violence
-
Belgrade, 17 May 2023Serbia focused on attracting new investments
-
Belgrade, 15 May 2023Continuation of engagement of UNMIK of crucial importance for Serbia
-
Belgrade, 15 May 2023EU membership remains Serbia’s strategic commitment